Thu. Dec 7th, 2023
    The MONARCH Platform: Revolutionizing Lung Cancer Diagnosis and Treatment

    REDWOOD CITY, Calif., Nov. 13, 2023 /PRNewswire/ — Johnson & Johnson MedTech*¬†announced a groundbreaking milestone in the fight against lung cancer: the MONARCH Platform and MONARCH Bronchoscope have received regulatory approval in China. This approval marks a significant advancement as the platform becomes the first minimally invasive, robotic-assisted technology approved for peripheral lung procedures in China. Furthermore, it is the first J&J MedTech robotic-assisted technology to gain regulatory approval in the country, expanding its global reach beyond the United States.

    The MONARCH Platform, in conjunction with the MONARCH Bronchoscope, is designed to provide innovative bronchoscopic visualization and access to adult patient airways for diagnostic and therapeutic procedures. This state-of-the-art device empowers physicians with minimally invasive, robotic-assisted technology to perform peripheral lung procedures with unrivaled precision and efficiency.

    Lung cancer is a pervasive and devastating disease that claims the lives of millions worldwide, with nearly 40% of cases diagnosed in China alone. The MONARCH Platform’s ability to reach small, deep-seated peripheral nodules at an earlier stage is a game-changer in diagnosing and treating lung cancer. These nodules are notoriously difficult to reach, hindering early-stage diagnosis and treatment, which are crucial for improving survival rates.

    Will Song, President of Johnson & Johnson MedTech China, expressed his enthusiasm about the approval, stating, “MONARCH is poised to aid physicians in China as they combat one of the most prevalent and deadly diseases in the country.” By introducing this groundbreaking technology, Johnson & Johnson MedTech aims to transform the landscape of interventional care, revolutionizing the future of healthcare for lung cancer patients.

    Adrian Whitford, President of MONARCH, emphasized the MONARCH team’s unwavering commitment to innovation, stating, “Expanding the reach of flexible robotic-assisted devices for lung procedures to countries worldwide is part of our vision to deliver breakthrough technology that improves clinical outcomes for patients fighting diseases like lung cancer.” This approval in China further cemented the MONARCH Platform’s status as a global leader in robotic-assisted bronchoscopy.

    The MONARCH Platform has already made a significant impact in the United States, with over 35,000 successful cases. Johnson & Johnson MedTech’s dedication to driving scientific innovation has led to breakthrough solutions in surgery, orthopedics, vision, and interventional care. By harnessing the power of purposeful technology, the company is revolutionizing medical intervention, saving lives, and ushering in a future where healthcare solutions are smarter, less invasive, and more personalized.


    1. What is the MONARCH Platform?
    2. The MONARCH Platform is a minimally invasive, robotic-assisted technology approved for bronchoscopy to provide diagnostic and therapeutic procedures for lung diseases.

    3. What makes the MONARCH Platform unique?
    4. The MONARCH Platform offers physicians unparalleled precision and access to small, hard-to-reach peripheral lung nodules, enabling early-stage diagnosis and treatment of lung cancer.

    5. What is the impact of early-stage lung cancer detection?
    6. Early detection of lung cancer significantly increases survival rates by allowing for timely and effective treatment.

    7. How many patients are diagnosed with lung cancer each year?
    8. There are more than two million patients diagnosed with lung cancer worldwide annually, with nearly 40% of cases in China.

    9. How has the MONARCH Platform been used so far?
    10. The MONARCH Platform has been utilized in over 35,000 cases in the United States, showcasing its effectiveness and clinical impact.

    *Comprising the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson’s MedTech segment.

    Source: Johnson & Johnson MedTech –